Latest Cash Runway News

NuEnergy Gas Limited has locked in a fully funded US$88 million contract with PT Beijing Energy Linking to develop its Tanjung Enim POD 1 project in Indonesia, targeting first gas sales in early 2027 under an Early Gas Sales Initiative.

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Omega Oil & Gas has kicked off a fully funded drilling program in Queensland’s Taroom Trough, backed by a strong $102 million cash position and no debt, aiming to unlock significant oil and gas volumes.

Aeeris Ltd has boosted its Annual Recurring Revenue by 9.1% year-on-year to $3.84 million, driven by an 18.6% rise in fixed subscription revenue and a strategic shift towards enterprise clients.

Great Dirt Resources has sharpened its lithium exploration focus in the Pilbara while confirming high-grade manganese assays in NSW, maintaining a robust cash position to fund its growth plans.

Lion Energy has locked in funding and government approval for its Bula Karang-1 well in Indonesia, targeting a September spud, while winding down its hydrogen project to focus on core upstream oil and gas activities.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Syntara secured positive FDA feedback for its Phase 2b amsulostat trial in myelofibrosis and raised $8 million to extend its cash runway to Q3 2027, while preliminary data showed promising brain inflammation reduction in a Parkinson’s-related disorder.

Astral Resources has boosted its Mandilla Gold Project resource to 1.74 million ounces of gold, with drilling confirming significant mineralisation and the Definitive Feasibility Study progressing towards completion in early 2027.

Radiopharm Theranostics (ASX: RAD) has requested an immediate voluntary suspension of its shares pending a material capital raising announcement expected before markets open on 27 July 2026.

CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.

Starpharma Holdings is raising approximately $32 million through a fully underwritten 1-for-7.5 renounceable entitlement offer priced at $0.57 per share, discounting the stock by 25%. Proceeds will fund the DEP HER2-Lu Phase 1 trial and expand its dendrimer-based oncology pipeline.